Chemists at Scripps Research in La Jolla say they have pulled off a bold molecular renovation of fentanyl, carving out its chemical core and dropping in a compact substitute that keeps the powerful pain relief in animals while sharply dialing down the drug’s worst traits. In lab tests and mouse studies, the experimental compound preserved strong analgesia yet showed markedly less respiratory depression and weaker signs of addiction risk.
The team did not simply polish fentanyl’s edges. They replaced its central ring with a tight 2-azaspiro[3.3]heptane scaffold, a topological overhaul that changed both potency and how the molecule behaves in the body. So far, the work lives entirely in laboratory assays and mouse models, with early data described in a peer-reviewed chemistry letter and flagged by the institute as a proof-of-concept path toward opioids with a wider safety margin. Researchers stress that human trials are a distant prospect.
Local coverage in the San Diego Business Journal on March 20, 2026 pushed the study beyond specialist circles and checked in with the Janda laboratory about the chemistry and what comes next. The piece identified Arran Stewart as the paper’s first author and reported that the project was backed by the Shadek Family Foundation. Scripps researchers told the outlet they plan to treat the new spirocore as a modular blueprint, tuning signaling, exposure and potency to generate potential drug candidates or even protective vaccines…